Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report

被引：0
作者：
Rodriguez-Ferreras, A. [1 ]
Zapico-Garcia, I [1 ]
机构：
[1] Hosp Univ Cent Asturias, Unidad Gest Clin Farm, Avda Roma S-N, Oviedo 33011, Spain
来源：
ANALES DEL SISTEMA SANITARIO DE NAVARRA | 2019年 / 42卷 / 01期
关键词：
Blinatumomab; Philadelphia chromosome negative; Stem cell transplantation; Minimal residual disease; Refractory acute lymphoblastic leukemia; PHASE-II;
D O I：
10.23938/ASSN.0392
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy. Nevertheless, there is little evidence about its role as an off label enhancer of cytological remission prior to stem cell transplantation (SCT). We describe the case of a patient with an excellent performance status who was allowed to undergo alogenic SCT after a single blinatumomab cycle, as well as the management of adverse events and the observed results.
引用
收藏
页码：75 / 78
页数：4
相关论文
共 50 条
  • [41] Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
    Locatelli, Franco
    Zugmaier, Gerhard
    Mergen, Noemi
    Bader, Peter
    Jeha, Sima
    Schlegel, Paul-Gerhardt
    Bourquin, Jean-Pierre
    Handgretinger, Rupert
    Brethon, Benoit
    Roessig, Claudia
    Kormany, William N.
    Viswagnachar, Puneeth
    Chen-Santel, Christiane
    BLOOD ADVANCES, 2022, 6 (03) : 1004 - 1014
  • [42] Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia
    Jeyakumar, Nikeshan
    Aldoss, Ibrahim
    Yang, Dongyun
    Mokhtari, Sally
    Gendzekhadze, Ketevan
    Khaled, Samer
    O'Donnell, Margaret
    Palmer, Joycelynne
    Song, Joo Y.
    Marcucci, Guido
    Stein, Anthony S.
    Forman, Stephen J.
    Pullarkat, Vinod A.
    Chen, Wei
    Wu, Xiwei
    Nakamura, Ryotaro
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (06) : 851 - 858
  • [43] Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia
    Ribera, Josep-Maria
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1057 - 1067
  • [44] Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
    Rambaldi, Alessandro
    Ribera, Josep-Maria
    Kantarjian, Hagop M.
    Dombret, Herve
    Ottmann, Oliver G.
    Stein, Anthony S.
    Tuglus, Catherine A.
    Zhao, Xiaoyue
    Kim, Christopher
    Martinelli, Giovanni
    CANCER, 2020, 126 (02) : 304 - 310
  • [45] Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report
    Fan, Shengxuan
    Wang, Lina
    Lu, Yaoyao
    Li, Zijian
    ANNALS OF HEMATOLOGY, 2024, 103 (02) : 525 - 532
  • [46] Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
    Delea, Thomas E.
    Amdahl, Jordan
    Boyko, Diana
    Hagiwara, May
    Zimmerman, Zachary F.
    Franklin, Janet L.
    Cong, Ze
    Hechmati, Guy
    Stein, Anthony
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (09) : 911 - 922
  • [47] Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
    Barlev, Arie
    Lin, Vincent W.
    Katz, Aaron
    Hu, Kuolung
    Cong, Ze
    Barber, Beth
    ADVANCES IN THERAPY, 2017, 34 (01) : 148 - 155
  • [48] Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
    Arie Barlev
    Vincent W. Lin
    Aaron Katz
    Kuolung Hu
    Ze Cong
    Beth Barber
    Advances in Therapy, 2017, 34 : 148 - 155
  • [49] Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan
    Imamura, T.
    Kiyokawa, N.
    Kato, M.
    Imai, C.
    Okamoto, Y.
    Yano, M.
    Ohki, K.
    Yamashita, Y.
    Kodama, Y.
    Saito, A.
    Mori, M.
    Ishimaru, S.
    Deguchi, T.
    Hashii, Y.
    Shimomura, Y.
    Hori, T.
    Kato, K.
    Goto, H.
    Ogawa, C.
    Koh, K.
    Taki, T.
    Manabe, A.
    Sato, A.
    Kikuta, A.
    Adachi, S.
    Horibe, K.
    Ohara, A.
    Watanabe, A.
    Kawano, Y.
    Ishii, E.
    Shimada, H.
    BLOOD CANCER JOURNAL, 2016, 6 : e419 - e419
  • [50] Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia
    Elitzur, Sarah
    Arad-Cohen, Nira
    Barzilai-Birenboim, Shlomit
    Ben-Harush, Miriam
    Bielorai, Bella
    Elhasid, Ronit
    Feuerstein, Tamar
    Gilad, Gil
    Gural, Alexander
    Kharit, Mira
    Litichever, Naomi
    Nirel, Ronit
    Weinreb, Sigal
    Wolach, Ofir
    Toren, Amos
    Izraeli, Shai
    Jacoby, Elad
    PEDIATRIC BLOOD & CANCER, 2019, 66 (10)
12345